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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To review and summarise the existing evidence of the relationship between maternal methylxanthine (including caffeine) consumption
(or by any other method of administration) versus no intervention, placebo or a different methylxanthine, before birth with the
intention to influence outcomes in preterm newborns, with particular focus on cardiorespiratory adaptation at birth and long-term
neurodevelopmental outcomes.
B A C K G R O U N D
Description of the condition
The transition from fetal to newborn life involves major physi-
ological adaptations essential for survival. In the fetus, the lungs
are fluid-filled and gas exchange occurs across the placenta. The
pulmonary vascular resistance is high and pulmonary blood flow
is low. After birth, the infant is separated from the placental circu-
lation when the umbilical cord is clamped. This leads to a switch
to pulmonary gas exchange and a major cardiovascular reorganisa-
tion within minutes after birth (Hooper 2015). Many preterm in-
fants will need assistance with breathing after birth, as they suffer
from an excess of lung fluid which needs to be cleared, and reduced
surfactant pools, limiting lung compliance (Hillman 2012). It is
therefore crucial to support the infant in the perinatal period to op-
timise successful lung aeration and an uneventful cardiorespiratory
transition after birth. At present, efforts to support the preterm
infant have focused largely on postnatal management. Recent data
from studies suggest that ante- and perinatal treatments may fur-
ther help to improve postnatal management (Dekker 2017). One
of these treatments is maternal antenatal methylxanthine (includ-
ing caffeine), when applied transdermally, orally or by intravenous
route. The treatment with methylxanthines is proposed to im-
prove respiratory drive (frequency of breaths), respiratorymechan-
ics (depth of breaths) and to help overcome apnoea (i.e. reduce
the length of breath-holding episodes).
Description of the intervention
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The Royal College of Obstetricians and Gynaecologists (RCOG)
states that the “current advice issued by the National Institute
for Health and Care Excellence (NICE) is that pregnant women
should limit their consumption of caffeine to 300 milligrams a
day” (NICE 2008; RCOG 2011). A large prospective observa-
tional study by the Care Study Group in 2010 concluded that an-
tenatal caffeine consumption was associated with fetal growth re-
striction, particularly with daily caffeine intake of 200 mg or more
(CARE Study Group 2010). Our National Health Service (NHS)
website advise pregnant women to restrict their daily caffeine in-
take to 200mg (NHS 2018). Taking these guidelines into account,
we propose to look into the studies where pregnant women re-
ceivedmethylxanthine (including caffeine) by oral, intravenous or
other routes (e.g. dermal patch) in the last month prior to preterm
delivery, in doses less than or equal to 200 mg with the intention
to positively influence the outcome of the preterm baby.
How the intervention might work
Methylxanthines, in particular caffeine and theophylline, have
been used in the treatment of apnoea of prematurity. They act
by stimulating the respiratory centre in the medulla, increasing
sensitivity to carbon dioxide, increasing skeletal muscle tone, in-
creasing diaphragmatic contractility, increasing minute volume,
increasing metabolic rate and increasing oxygen consumption
(Abdel-Hady 2015). Caffeine is also a central nervous system
stimulant and a somnolytic agent. Caffeine, through its adeno-
sine blocking effect, modulates several neurotransmitters like
dopamine, serotonin, noradrenaline, acetylcholine and gamma-
aminobutyric acid (Abdel-Hady 2015; Shrestha 2017). Caffeine
also stimulates the myocardium and increases heart rate, thus im-
proving cardiac output, stroke volume and mean arterial blood
pressure (Shrestha 2017).
At the molecular level, methylxanthines are adenosine receptor
antagonists as well as being phosphodiesterase inhibitors (Shrestha
2017). Adenosine is a purine nucleoside in the brain and has four
receptors - A1, A2a, A2b and A3 (Shrestha 2017). These recep-
tors, through their effects on adenylate cyclase can cause central
respiratory depression, sedation and smooth muscle constriction
(Shrestha 2017). Caffeine (a trimethylxanthine), is a specific in-
hibitor of at least A1 and A2a and thus manifests its effects in
preterm neonates (Shrestha 2017). Caffeine’s effect as a phospho-
diesterase inhibitor and a calcium channel binder is at a much
higher level and further research is needed on these pathways of
action (Shrestha 2017). A systematic review showed that caffeine’s
therapeutic window is wider and that it has fewer adverse effects
compared to theophylline, making it the more preferred first-line
therapy for apnoea of prematurity (Schoen 2014).
There is evidence thatmaternally consumed caffeine passes the pla-
cental barrier freely (Sengpiel 2013). Animal studies have shown
that administration of methylxanthine (aminophylline) to preg-
nant rabbits may enhance fetal lung maturation by stimulating
pulmonary surfactant production prior to delivery (Ayromlooi
1981). There is evidence from neonatal randomised controlled tri-
als (RCTs) that early methylxanthine (including caffeine) admin-
istration (within 72 hours of birth) is safe and results in reduced
apnoea and improved respiratory outcomes (Schmidt 2006). A
recent pilot RCT of very early caffeine administered before two
hours of age compared to after 12 hours of life showed an im-
provement in haemodynamics in preterms in terms of blood pres-
sure, systemic blood flow and right ventricular output (Katheria
2015). In models of perinatal brain injury, caffeine is neuropro-
tective against periventricular white matter injury and hypoxic is-
chaemic encephalopathy (Kreutzer 2014). Methylxanthines have
also been shown to improve rate of mortality and neurodevelop-
mental outcomes in preterms (Khurana 2017). However, still very
little is known regarding maternal methylxanthine intake in the
last month prior to delivery and its effects on the cardiorespira-
tory adaptation of the preterm infant and long-term neurological
outcomes.
Why it is important to do this review
About 15 million premature babies (defined as born less than
37 weeks of gestation) are born worldwide each year. These in-
fants represent 11% of all newborn babies (Howson 2013). De-
spite three decades of multiple advances in the field of neonatal
medicine, preterm birth is still the second largest cause of death
in children under five years of age (Lawn 2004). One of the goals
of ’Healthy People 2020’ is to reduce low birthweight (LBW) and
very low birthweight (VLBW) (HHS 2010).
European consensus guidelines on the management of respiratory
distress syndrome (RDS) reiterates the importance of antenatal
corticosteroids in the role of RDS prevention. Antenatal corticos-
teroids also improve the cardiac function following preterm deliv-
ery (Hillman 2012). However, the transition from fetus to new-
born is one of the most complex physiological adaptations involv-
ing multiple organs. Initiation of breathing and maintenance of
adequate respiratory efforts is one of the major contributors to a
successful adaptation. The preterm newborn is significantly dis-
advantaged compared to the term newborn during this adapta-
tion phase due to the lack of adequately developed lungs, lead-
ing to difficulty with ventilation, reduced surfactant and reduced
compliance (Hillman 2012). However, the adaptation of preterm
lungs has been helped postnatally by positive pressure ventilation
and methylxanthine. Multiple studies, including RCTs (Schmidt
2006), have proven the benefit of methylxanthines on preterm in-
fant health, as illustrated above. Given the complex nature of the
transition and adaptation of the fetus to the preterm newborn and
the numerous factors that play a role in this, earlier support in this
transition process may positively affect cardiorespiratory adapta-
tion. A smooth transition will aid improved cardiorespiratory and
neurodevelopmental outcomes, improving mortality and morbid-
ity - a ’Healthy People 2020’ goal (HHS 2010). One such mode of
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support might be the antenatal administration of methylxanthine
(including caffeine) to support the transition from fetus to preterm
newborn. The authors noted a significant gap in the literature, in
terms of systematic reviews on this topic, and therefore propose
to review the body of evidence available currently, with the aim of
improving knowledge of whether a preterm infant benefits from
maternal-to-fetal transfer of methylxanthines, prior to birth.
O B J E C T I V E S
To review and summarise the existing evidence of the relationship
between maternal methylxanthine (including caffeine) consump-
tion (or by any other method of administration) versus no inter-
vention, placebo or a different methylxanthine, before birth with
the intention to influence outcomes in preterm newborns, with
particular focus on cardiorespiratory adaptation at birth and long-
term neurodevelopmental outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We plan to include all published, unpublished and ongoing ran-
domised controlled trials (RCTs) that compare the administration
of maternal caffeine versus no intervention, placebo or a different
methylxanthine in the last month of pregnancy, including up to
the point of delivery, in women who give birth to preterm in-
fants. We will also include studies comparing the administration
of a methylxanthine (other than caffeine) to placebo or no inter-
vention. We will also include quasi-randomised and cluster-ran-
domised trials, but we are aware of the increased risk of bias in
these type of trials (please refer to the sections on Unit of analysis
issues and Sensitivity analysis). We will also make sure we report
if there were trials controlled for dietary intake of caffeine.
Types of participants
1. Pregnant women in the last month of their pregnancy who
are at risk of giving birth to a preterm infant and received
methylxanthines (including caffeine) or placebo prior to giving
birth (by any mode of delivery) before or at 36 + 6 weeks of
gestation.
2. Preterm infants (including 23 to 36 + 6 weeks gestational
age) born to the above mentioned cohorts of women involved in
the studies.
Please note that though the preterm infant is being included for
outcome measures, they are not receiving any intervention. The
intervention is being given to the mother prior to the infant being
born.
We will exclude the following conditions from our review.
1. Cases of antepartum haemorrhage, cord prolapse or other
causes of perinatal asphyxia leading to hypoxic ischaemic
encephalopathy.
2. Any chromosomal anomalies.
3. Any congenital heart disease.
4. Any surgical conditions, such as congenital diaphragmatic
hernia.
5. Apgar score less than 5 at five minutes of age.
Types of interventions
Administration of methylxanthines (including caffeine) or a
placebo or no intervention in the last month of pregnancy in
women who had a preterm delivery. Themethylxanthines (includ-
ing caffeine) could have been administered either by oral intake,
intravenous infusion or any other route (e.g. dermal patch) in
doses less than or equal to 200 mg of caffeine (one mug of instant
coffee is 100 mg).
Types of outcome measures
Primary outcomes
The effect of maternal methylxanthine (including caffeine) intake
in the last month on the preterm infant’s cardiorespiratory transi-
tion. In particular, we will focus on:
1. the need for and duration of intubation and ventilation;
2. the incidence of arterial hypotension (mean arterial blood
pressure less than the gestational age or need for fluid
resuscitation or inotropic support);
3. neurodevelopmental outcome at two years of age, assessed
by the Bayley Scales of Infant and Toddler Development
(BSITD; Bayley 2006), or other standardised
neurodevelopmental assessment tools.
Secondary outcomes
The effect of maternal methylxanthine (including caffeine) intake
in the last month (including the perinatal period) on:
1. incidence of stillbirths;
2. the need for any pulmonary surfactant;
3. the incidence and severity of apnoea within the first 120
hours of life;
4. bronchopulmonary dysplasia, defined by the need for
supplemental oxygen at a postmenstrual age of 36 weeks;
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5. haemodynamically significant patent ductus arteriosus
(based on echocardiographic evidence) needing pharmacologic
closure or surgical ligation;
6. ultrasonographic signs of brain injury, including
intraventricular haemorrhage (grades 3 and 4 of which will be
categorised as severe), cystic periventricular leukomalacia,
haemorrhagic parenchymal infarction, moderate to severe
posthaemorrhagic ventricular dilatation or echodensity persisting
> three to four weeks;
7. necrotising enterocolitis;
8. retinopathy of prematurity;
9. neonatal death;
10. total duration of stay in the neonatal intensive care unit
(NICU);
11. any adverse maternal outcomes, e.g. insomnia, headache,
nausea, diarrhoea, etc.
Search methods for identification of studies
The following methods section of this protocol is based on a stan-
dard template used by Cochrane Pregnancy and Childbirth.
Electronic searches
We will search Cochrane Pregnancy and Childbirth’s Trials Regis-
ter by contacting their Information Specialist.
The Register is a database containing over 25,000 reports of con-
trolled trials in the field of pregnancy and childbirth. It represents
over 30 years of searching. For full current search methods used
to populate Pregnancy and Childbirth’s Trials Register including
the detailed search strategies for CENTRAL, MEDLINE, Em-
base and CINAHL; the list of handsearched journals and confer-
ence proceedings, and the list of journals reviewed via the current
awareness service, please follow this link.
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is
maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full text of all
relevant trial reports identified through the searching activities de-
scribed above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a spe-
cific Pregnancy and Childbirth review topic (or topics), and is
then added to the Register. The Information Specialist searches
the Register for each review using this topic number rather than
keywords. This results in amore specific search set that will be fully
accounted for in the relevant review sections (Included, Excluded,
Awaiting Classification or Ongoing).
In addition, we will search ClinicalTrials.gov and the
WorldHealthOrganization (WHO) International Clinical Trials
Registry Platform for unpublished, planned and ongoing trial re-
ports, using the search terms listed in Appendix 1.
Searching other resources
We will search the reference lists of retrieved studies. We will not
apply any language or date restrictions.
Data collection and analysis
The following methods section of this protocol is based on a stan-
dard template used by Cochrane Pregnancy and Childbirth.
Selection of studies
A minimum of two review authors will independently assess for
inclusion all the potential studies we identify as a result of the
search strategy. We will resolve any disagreement through discus-
sion or, if required, we will consult a further review author.
We will create a study flow diagram to map out the number of
records identified, included and excluded.
Data extraction and management
We will design a form to extract data. For eligible studies, at least
two independent review authors will extract the data using the
agreed form. The information that we will extract from the trial
reports will also include trial dates, sources of trial funding, trialist
declarations of interest, etc. We will also report if there are trials
controlled for dietary intake of caffeine. We will resolve discrep-
ancies through discussion or, if required, we will consult a further
review author. We will enter data into Review Manager software
(Review Manager 2014), and check for accuracy. When informa-
tion regarding any of the above is unclear, we will attempt to con-
tact authors of the original reports to provide further details.
Assessment of risk of bias in included studies
A minimum of two review authors will independently assess risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreement by discussion or by involving a
further assessor.
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(1) Random sequence generation (checking for possible
selection bias)
We will describe for each included study the method used to gen-
erate the allocation sequence in sufficient detail to allow an assess-
ment of whether it should produce comparable groups.
We will assess the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number); or
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We will describe for each included study the method used to con-
ceal allocation to interventions prior to assignment and will assess
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We will assess the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We will describe for each included study the methods used, if
any, to blind study participants and personnel from knowledge of
which intervention a participant received. We will consider that
studies are at low risk of bias if they were blinded, or if we judge
that the lack of blinding would be unlikely to affect results. We
will assess blinding separately for different outcomes or classes of
outcomes.
We will assess the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We will describe for each included study the methods used, if any,
to blind outcome assessors from knowledge of which intervention
a participant received. We will assess blinding separately for dif-
ferent outcomes or classes of outcomes.
We will assess methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We will describe for each included study, and for each outcome
or class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We will state whether attrition
and exclusions were reported and the numbers included in the
analysis at each stage (compared with the total randomised par-
ticipants), reasons for attrition or exclusion where reported, and
whether missing data were balanced across groups or were related
to outcomes. Where sufficient information is reported, or can be
supplied by the trial authors, we will re-include missing data in
the analyses which we undertake.
We will assess methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ’as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We will describe for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We will assess the methods as:
• low risk of bias (where it is clear that all of the study’s
prespecified outcomes and all expected outcomes of interest to
the review have been reported);
• high risk of bias (where not all the study’s prespecified
outcomes have been reported; one or more reported primary
outcomes were not prespecified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We will describe for each included study any important concerns
we have about other possible sources of bias.
We will assess whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We will make explicit judgements about whether studies are at
high risk of bias, according to the criteria given in the Cochrane
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Handbook for Systematic Reviews of Interventions (Higgins 2011).
With reference to (1) to (6) above, we will assess the likely magni-
tude and direction of the bias and whether we consider it is likely
to impact on the findings. We will explore the impact of the level
of bias through undertaking sensitivity analyses - see Sensitivity
analysis.
Assessment of the quality of the evidence using the
GRADE approach
We will assess the quality of the evidence using the GRADE ap-
proach, as outlined in the GRADE handbook, in order to assess
the quality of the body of evidence relating to the following out-
comes for the main comparisons. We will compare the interven-
tion to either placebo, another intervention or to no intervention.
We will assess the effect of maternal methylxanthine (including
caffeine) intake in the last month of pregnancy on the preterm
infant’s cardiorespiratory transition. In particular, we will focus
on:
1. the need for and duration of intubation and ventilation;
2. the incidence of arterial hypotension (mean arterial blood
pressure less than the gestational age or need for fluid
resuscitation or inotropic support;
3. neurodevelopmental outcome at two years of age, assessed
by the Bayley Scales of Infant and Toddler Development
(BSITD; Bayley 2006), or other standardised
neurodevelopmental assessment tools.
We will use the GRADEpro Guideline Development Tool to im-
port data from Review Manager 5 in order to create ’Summary of
findings’ tables (Review Manager 2014). We will produce a sum-
mary of the intervention effect and a measure of quality for each
of the above outcomes using the GRADE approach. The GRADE
approach uses five considerations (study limitations, consistency
of effect, imprecision, indirectness and publication bias) to assess
the quality of the body of evidence for each outcome. The ev-
idence can be downgraded from ’high quality’ by one level for
serious (or by two levels for very serious) limitations, depending
on assessments for risk of bias, indirectness of evidence, serious
inconsistency, imprecision of effect estimates or potential publi-
cation bias.
Measures of treatment effect
Dichotomous data
For dichotomous data, we will present results as summary risk
ratio (RR) with 95% confidence intervals (CIs).
Continuous data
For continuous data, we will use the mean difference (MD) if
outcomes are measured in the same way between trials.We will use
the standardised mean difference (SMD) to combine trials that
measure the same outcome, but use different methods.
Unit of analysis issues
Cluster-randomised trials
If we include cluster-randomised trials in the analyses along with
individually randomised trials, we will adjust their sample sizes
using the methods described in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Section 16.3.4 or 16.3.6; Higgins
2011), using an estimate of the intracluster correlation coefficient
(ICC) derived from the trial (if possible), from a similar trial or
from a study of a similar population. If we use ICCs from other
sources, we will report this and conduct sensitivity analyses to in-
vestigate the effect of variation in the ICC. If we identify both
cluster-randomised trials and individually-randomised trials, we
plan to synthesise the relevant information. We will consider it
reasonable to combine the results from both if there is little het-
erogeneity between the study designs and the interaction between
the effect of intervention and the choice of randomisation unit is
considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a subgroup analysis to investigate the effects of the
randomisation unit.
Other unit of analysis issues
Other unit of analysis issues: should our search reveal trials in
Pregnancy and Childbirth which include outcomes for multiple
gestations (twin pregnancies), we will report the special meth-
ods to analyse data relating to multiple gestations as outlined in
Cochrane Pregnancy and Childbirth methodological guidelines
and theCochrane Handbook for Systematic Reviews of Interventions
(Sections 9.3.7 and 16.3; Higgins 2011).
If we identify studies that include more than two intervention
groups, we will use ’multiple-treatments meta-analysis’ methods
(Section 16.6.3; Higgins 2011).
Dealing with missing data
For included studies, wewill note levels of attrition.Wewill explore
the impact of including studies with high levels of missing data
in the overall assessment of treatment effect by using sensitivity
analysis.
For all outcomes, we will carry out analyses, as far as possible,
on an intention-to-treat basis, i.e. we will attempt to include all
participants randomised to each group in the analyses, and all
participants will be analysed in the group to which they were
allocated, regardless of whether or not they received the allocated
intervention. The denominator for each outcome in each trial
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will be the number randomised minus any participants whose
outcomes are known to be missing.
Assessment of heterogeneity
We will assess statistical heterogeneity in each meta-analysis using
the Tau², I² and Chi² statistics. We will regard heterogeneity as
substantial if I² is greater than 30% and either Tau² is greater than
zero, or there is a low P value (less than 0.10) in the Chi² test for
heterogeneity.
Assessment of reporting biases
If there are 10 or more studies in the meta-analysis we will in-
vestigate reporting biases (such as publication bias) using funnel
plots. We will assess funnel plot asymmetry visually. If asymmetry
is suggested by a visual assessment, we will perform exploratory
analyses to investigate it.
Data synthesis
We will carry out statistical analysis using Review Manager 5 soft-
ware (Review Manager 2014). We will use a fixed-effect meta-
analysis for combining data where it is reasonable to assume that
studies are estimating the same underlying treatment effect, i.e.
where trials are examining the same intervention, and the trials’
populations and methods are judged sufficiently similar. If there
is clinical heterogeneity sufficient to expect that the underlying
treatment effects differ between trials, or if substantial statistical
heterogeneity is detected, we will use a random-effects meta-anal-
ysis to produce an overall summary if an average treatment effect
across trials is considered clinically meaningful. We will treat the
random-effects summary as the average of the range of possible
treatment effects and we will discuss the clinical implications of
treatment effects differing between trials. If the average treatment
effect is not clinically meaningful we will not combine trials.
If we use random-effects analyses, we will present the results as the
average treatment effect with 95% CIs, and the estimates of Tau²
and I².
Subgroup analysis and investigation of heterogeneity
If we identify substantial heterogeneity, we will investigate it us-
ing subgroup analyses and sensitivity analyses. We will consider
whether an overall summary is meaningful, and if it is, use a ran-
dom-effects analysis to produce it.
We plan to carry out the following subgroup analyses.
1. Extreme preterm deliveries (23 + 0 to 26 + 6 weeks) versus
early preterm deliveries (27 + 0 to 31 + 6).
2. Early preterm deliveries (27 + 0 to 31 + 6 weeks) versus late
preterm deliveries (32 + 0 to 36 + 6 weeks).
3. Intake of maternal methylxanthine (including caffeine) for
less than or equal to 24 hours before preterm delivery versus
intake of maternal methylxanthine (including caffeine) for more
than 24 hours before preterm delivery.
4. The dose of intake of maternal methylxanthine (including
caffeine) being less than or equal to 100 mg versus the dose of
intake of maternal methylxanthine (including caffeine) being
more than 100 mg to a maximum of 200 mg.
We will use the following outcomes in all of the above subgroup
analyses.
The effect of maternal methylxanthine (including caffeine) intake
in the last month of pregnancy on the preterm infant’s cardiores-
piratory transition. In particular, we will focus on:
1. the need for and duration of intubation and ventilation;
2. the incidence of arterial hypotension (mean arterial blood
pressure less than the gestational age or need for fluid
resuscitation or inotropic support);
3. neurodevelopmental outcome at two years of age, assessed
by the Bayley Scales of Infant and Toddler Development
(BSITD; Bayley 2006), or other standardised
neurodevelopmental assessment tools.
We will assess subgroup differences by interaction tests available
within ReviewManager 5 (ReviewManager 2014).We will report
the results of subgroup analyses quoting the Chi2 statistic and P
value, and the interaction test I² value.
If we identify studies that include more than two intervention
groups, we will use ’multiple-treatments meta-analysis’ methods
(Section 16.6.3; Higgins 2011).
Sensitivity analysis
We will carry out a sensitivity analysis with aims to explore the
effects of the trial quality assessed by allocation concealment and
other risk of bias components, by omitting studies rated as ’high
risk of bias’ for these components. We will restrict this to the
primary outcomes.
If we identify quasi-randomised trials we will do a sensitivity anal-
ysis to see if this makes any difference to the overall analysis.
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A P P E N D I C E S
Appendix 1. Search terms for ClinicalTrials.gov and ICTRP
caffeine AND pregnancy
caffeine AND antenatal
caffeine AND prenatal
methylxanthine(s) AND pregnancy
methylxanthine(s) AND antenatal
methylxanthine(s) AND prenatal
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